+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Acute Kidney Injury Treatment Market (AKI) - Global Forecast 2026-2032- Product Image
Acute Kidney Injury Treatment Market (AKI) - Global Forecast 2026-2032- Product Image
Sale

Acute Kidney Injury Treatment Market (AKI) - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5134204
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Acute Kidney Injury Treatment Market is projected to reach USD 2.96 Billion in 2026. It is expected to continue growing at a CAGR of 8.07%, reaching USD 4.73 Billion by 2032.

Acute kidney injury treatment is moving from reactive renal rescue to earlier risk stratification, fluid stewardship, nephrotoxin avoidance, and precision use of kidney replacement therapy. The clinical need is substantial: KDIGO defines AKI by rapid rises in serum creatinine or reduced urine output, and peer-reviewed epidemiology consistently shows AKI in approximately 10% to 15% of hospitalized adults and in more than half of many intensive care unit populations.

The treatment landscape spans supportive care, hemodynamic optimization, sepsis management, electrolyte and acid-base correction, intermittent hemodialysis, continuous renal replacement therapy, peritoneal dialysis in selected settings, and emerging biomarker-guided pathways. Because AKI is associated with higher in-hospital mortality, longer length of stay, and increased risk of chronic kidney disease, focus is shifting toward prevention, early detection, and standardized care bundles rather than dialysis alone.

Transformative Shifts in the Acute Kidney Injury Treatment Landscape

The most important shift in acute kidney injury treatment is the recognition that timing, context, and phenotype matter. Large randomized trials, including AKIKI, ELAIN, IDEAL-ICU, and STARRT-AKI, have shown that accelerated initiation of kidney replacement therapy does not uniformly improve survival, reinforcing the need for individualized decisions based on hyperkalemia, acidosis, fluid overload, uremic complications, and trajectory of kidney function.

At the same time, hospitals are adopting nephrotoxin stewardship, electronic AKI alerts, balanced crystalloids for appropriate patients, sepsis protocols, and multidisciplinary ICU-nephrology pathways. Biomarkers such as NGAL, cystatin C, and TIMP-2 x IGFBP7 are gaining attention for risk assessment, while device innovation is improving CRRT anticoagulation, sorbent technology, ultrafiltration control, dose management, and remote monitoring.

Cumulative Impact of Artificial Intelligence on AKI Care

Artificial intelligence is adding cumulative value across AKI prevention, diagnosis, treatment selection, and post-discharge surveillance. Machine learning models trained on electronic health records can identify rising AKI risk before creatinine changes become clinically apparent, enabling earlier medication review, contrast-risk mitigation, and fluid management. Evidence remains implementation-dependent, but health systems are increasingly evaluating AI-enabled alerts for workflow integration, clinical escalation, and reduction of alert fatigue.

AI also supports CRRT operations through predictive maintenance, dose monitoring, anticoagulation assessment, and detection of filter clotting risk. In research, AI accelerates phenotyping by linking laboratory data, urine output, hemodynamics, medication exposure, comorbidities, and outcomes, which may help identify patients most likely to benefit from specific AKI treatment strategies.

Key Regional Insights for Acute Kidney Injury Treatment

North America leads adoption of ICU-based CRRT, AKI alerts, nephrology consultation pathways, and clinical trial participation, supported by advanced hospital infrastructure, electronic health record penetration, and reimbursement frameworks. Europe shows strong guideline alignment through KDIGO-informed practice, national kidney registries, and coordinated sepsis and critical care networks, while regional policy priorities emphasize medical device oversight, data protection, and cross-border evidence generation.

Asia-Pacific carries a large AKI burden because of population scale, rising diabetes and cardiovascular disease, infection-related AKI, and expanding access to critical care in China, India, Japan, South Korea, Australia, and ASEAN markets. Latin America, the Middle East, and Africa show diverse access patterns; tertiary centers increasingly offer CRRT and advanced dialysis support, but many facilities still face constraints in dialysis availability, trained staff, water quality, consumables, early referral systems, and continuity of post-discharge kidney care.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are expanding AKI treatment capacity through ICU modernization, broader dialysis availability, and regional procurement of cost-effective consumables, although access remains uneven between urban and rural hospitals. GCC countries benefit from high healthcare investment, advanced tertiary centers, and strong adoption potential for CRRT, AI-enabled monitoring, biomarker-enabled risk assessment, and nephrology specialty services.

The European Union emphasizes harmonized clinical standards, post-market device surveillance, and evidence-based implementation of diagnostics and dialysis technologies. BRICS nations represent high-volume clinical demand driven by population scale, infection burden, and rising noncommunicable disease, while G7 countries continue to shape innovation in AKI biomarkers, digital decision support, critical care protocols, and clinical research infrastructure. NATO-aligned health systems also prioritize resilient dialysis supply chains, surge capacity, and emergency preparedness for civilian and crisis-care settings.

Key Country Insights in Acute Kidney Injury Treatment

The United States remains a major innovation center for acute kidney injury treatment, with strong ICU penetration, clinical informatics, nephrology expertise, and medical technology adoption. Canada focuses on equitable access and evidence-based kidney care, while Mexico and Brazil face growing demand linked to diabetes, sepsis, hospital-acquired AKI, and uneven access to advanced dialysis, creating opportunities for scalable treatment delivery and workforce training.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have mature nephrology services and guideline-driven hospital pathways, while Russia combines large geographic demand with variable regional access to specialized AKI care. China and India represent the largest patient-volume opportunities in Asia due to population scale, critical care expansion, infection-related AKI, and rising chronic disease prevalence. Japan has advanced dialysis expertise and an aging population, South Korea supports technology-led hospital care and digital health adoption, and Australia benefits from strong critical care networks, kidney-health programs, and regional expertise in remote-care delivery.

Actionable Recommendations for AKI Treatment Leaders

Industry leaders should prioritize solutions that reduce preventable AKI, improve early recognition, and optimize kidney replacement therapy utilization. High-impact actions include embedding AKI risk scoring into electronic health records, pairing alerts with clinical response protocols, supporting pharmacist-led nephrotoxin stewardship, and investing in staff education for CRRT prescription, anticoagulation, vascular access, and fluid balance management.

Manufacturers and service providers should design offerings around total cost of care, not device sales alone. The strongest market positions will combine reliable consumables, training, interoperability, real-world evidence, AI-assisted monitoring, biomarker-compatible workflows, and post-discharge kidney follow-up to reduce progression to chronic kidney disease and readmission.

Research Methodology for the AKI Treatment Executive Summary

This executive summary is grounded in secondary research from peer-reviewed nephrology and critical care literature, KDIGO clinical practice guidance, major randomized trials on kidney replacement therapy timing, public health sources, regulatory publications, and hospital-care trend analysis. Insights were prioritized when supported by reproducible clinical evidence, guideline consensus, or well-documented healthcare infrastructure patterns.

The methodology applies triangulation across epidemiology, treatment standards, device adoption, regional healthcare capacity, and innovation signals. Market interpretation avoids unsupported revenue claims and focuses on data-backed drivers such as AKI incidence in hospitalized and ICU patients, dialysis access, biomarker adoption, AI implementation readiness, workforce capacity, supply-chain resilience, and health-system investment.

Conclusion: The Future of Acute Kidney Injury Treatment

Acute kidney injury treatment is becoming a prevention-led, data-enabled, and multidisciplinary field. The highest-value opportunities are in earlier detection, care standardization, safe dialysis delivery, biomarker-guided risk assessment, and integration of nephrology expertise across ICU, emergency, surgical, oncology, and post-discharge settings.

Organizations that align clinical evidence with operational execution will be best positioned to improve outcomes and strengthen adoption. As AKI remains common, costly, and strongly associated with mortality and chronic kidney disease, healthcare systems will reward solutions that demonstrate measurable reductions in complications, resource use, readmission, and long-term kidney damage.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Acute Kidney Injury Treatment Market, by Treatment Type
7.1. Introduction
7.2. Extracorporeal & Renal Replacement
7.2.1. Intermittent Hemodialysis
7.2.2. Continuous Renal Replacement Therapy (CRRT)
7.2.3. Peritoneal Dialysis
7.3. Pharmacologic Management
7.3.1. Diuretics
7.3.2. Hemodynamic & Renal Perfusion Agents
7.3.3. Metabolic & Electrolyte Agents
7.3.4. Anti-Infectives & Sepsis Adjuncts
7.3.5. Cytoprotective & Anti-Inflammatory Agents
7.4. Conservative & Supportive Management
7.4.1. Fluid Management
7.4.2. Electrolyte & Acid-Base Correction
7.4.3. Nutrition & Metabolic Support
7.5. Procedural Interventions
7.5.1. Vascular Or Peritoneal Access Placement
7.5.2. Obstruction Relief Procedures
8. Acute Kidney Injury Treatment Market, by AKI Type
8.1. Introduction
8.2. Intrarenal AKI
8.3. Postrenal AKI
8.4. Prerenal AKI
9. Acute Kidney Injury Treatment Market, by End User
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Hospitals
9.4. Specialty Clinics
10. Acute Kidney Injury Treatment Market, by Patient Age Group
10.1. Introduction
10.2. Neonates
10.3. Pediatrics
10.4. Adults
11. Acute Kidney Injury Treatment Market, by Region
11.1. Europe
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Middle East
11.6. Africa
12. Acute Kidney Injury Treatment Market, by Group
12.1. NATO
12.2. G7
12.3. European Union
12.4. BRICS
12.5. GCC
12.6. ASEAN
13. Acute Kidney Injury Treatment Market, by Country
13.1. United States
13.2. China
13.3. Germany
13.4. Canada
13.5. India
13.6. United Kingdom
13.7. Japan
13.8. Mexico
13.9. France
13.10. Brazil
13.11. Italy
13.12. Australia
13.13. Russia
13.14. South Korea
13.15. Spain
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Fresenius Medical Care AG
15.2. Baxter International, Inc.
15.3. B. Braun SE
15.4. DaVita Inc. by Optum, Inc.
15.5. Medtronic plc
15.6. Asahi Kasei Medical Co., Ltd.
15.7. Nikkiso Co., Ltd.
15.8. Nipro Corporation
15.9. bioMérieux SA
15.10. AstraZeneca PLC
15.11. Outset Medical, Inc.
15.12. Evotec SE
15.13. Siemens Healthineers AG
15.14. Abbott Laboratories
15.15. Terumo Corporation
15.16. Sysmex Corporation
15.17. Takeda Pharmaceutical Company Limited
15.18. SBI Biotech Co., Ltd.
15.19. Rockwell Medical, Inc.
15.20. Astellas Pharma Inc.
15.21. Medica S.p.A.
15.22. Alloksys Life Sciences
15.23. CalciMedica Inc.
15.24. CardioRenal Systems, Inc.
15.25. CSL Limited
15.26. Eliaz Therapeutics Inc.
15.27. F. Hoffmann-La Roche Ltd.
15.28. GE HealthCare Technologies Inc.
15.29. Novartis AG
15.30. Silver Creek Pharmaceuticals, Inc.
15.31. TORAY MEDICAL CO,.LTD.
List of Figures
FIGURE 1. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL EXTRACORPOREAL & RENAL REPLACEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL EXTRACORPOREAL & RENAL REPLACEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL EXTRACORPOREAL & RENAL REPLACEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL INTERMITTENT HEMODIALYSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL INTERMITTENT HEMODIALYSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL INTERMITTENT HEMODIALYSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL PERITONEAL DIALYSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL PERITONEAL DIALYSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL PERITONEAL DIALYSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PHARMACOLOGIC MANAGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PHARMACOLOGIC MANAGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PHARMACOLOGIC MANAGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL DIURETICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL DIURETICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL DIURETICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL HEMODYNAMIC & RENAL PERFUSION AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL HEMODYNAMIC & RENAL PERFUSION AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL HEMODYNAMIC & RENAL PERFUSION AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL METABOLIC & ELECTROLYTE AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL METABOLIC & ELECTROLYTE AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL METABOLIC & ELECTROLYTE AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ANTI-INFECTIVES & SEPSIS ADJUNCTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ANTI-INFECTIVES & SEPSIS ADJUNCTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ANTI-INFECTIVES & SEPSIS ADJUNCTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL CYTOPROTECTIVE & ANTI-INFLAMMATORY AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CYTOPROTECTIVE & ANTI-INFLAMMATORY AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CYTOPROTECTIVE & ANTI-INFLAMMATORY AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CONSERVATIVE & SUPPORTIVE MANAGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL CONSERVATIVE & SUPPORTIVE MANAGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL CONSERVATIVE & SUPPORTIVE MANAGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL FLUID MANAGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL FLUID MANAGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL FLUID MANAGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL ELECTROLYTE & ACID-BASE CORRECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ELECTROLYTE & ACID-BASE CORRECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ELECTROLYTE & ACID-BASE CORRECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL NUTRITION & METABOLIC SUPPORT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL NUTRITION & METABOLIC SUPPORT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL NUTRITION & METABOLIC SUPPORT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL PROCEDURAL INTERVENTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PROCEDURAL INTERVENTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL PROCEDURAL INTERVENTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL VASCULAR OR PERITONEAL ACCESS PLACEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL VASCULAR OR PERITONEAL ACCESS PLACEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL VASCULAR OR PERITONEAL ACCESS PLACEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL OBSTRUCTION RELIEF PROCEDURES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL OBSTRUCTION RELIEF PROCEDURES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL OBSTRUCTION RELIEF PROCEDURES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL INTRARENAL AKI MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL INTRARENAL AKI MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL INTRARENAL AKI MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL POSTRENAL AKI MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL POSTRENAL AKI MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL POSTRENAL AKI MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PRERENAL AKI MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PRERENAL AKI MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL PRERENAL AKI MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL NEONATES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL NEONATES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL NEONATES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL PEDIATRICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL PEDIATRICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL PEDIATRICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL ADULTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 88. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 89. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 90. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 91. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 92. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 93. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 94. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 122. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 124. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 125. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 126. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 127. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 128. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 129. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 130. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 131. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 133. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 134. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 135. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 136. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 137. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 138. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 139. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 141. NATO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. NATO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 143. NATO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 144. NATO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 145. NATO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 146. NATO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 147. NATO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 148. NATO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 149. NATO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 150. G7 ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. G7 ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 152. G7 ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 153. G7 ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 154. G7 ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 155. G7 ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 156. G7 ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 157. G7 ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 158. G7 ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 168. BRICS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. BRICS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 170. BRICS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 171. BRICS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 172. BRICS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 173. BRICS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 174. BRICS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 175. BRICS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 176. BRICS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 177. GCC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 178. GCC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 179. GCC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 180. GCC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 181. GCC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 182. GCC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 183. GCC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 184. GCC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 185. GCC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 186. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 187. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 188. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 189. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 190. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 191. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 192. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 193. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 194. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 195. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 196. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 197. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 198. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 199. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 200. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 201. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 202. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 203. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 204. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 205. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 206. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 207. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 208. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 209. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 210. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 211. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 212. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 213. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 214. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 215. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 216. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 217. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 218. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 219. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 220. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 221. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 222. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 223. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 224. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 225. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 226. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 227. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 228. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 229. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 230. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 231. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 232. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 233. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 234. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 235. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 236. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 237. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 238. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 239. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 240. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 241. UNITED KINGDOM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 242. UNITED KINGDOM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 243. UNITED KINGDOM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 244. UNITED KINGDOM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 245. UNITED KINGDOM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 246. UNITED KINGDOM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 247. UNITED KINGDOM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 248. UNITED KINGDOM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 249. UNITED KINGDOM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 250. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 251. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 252. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 253. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 254. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 255. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 256. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 257. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 258. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 259. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 260. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 261. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 262. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 263. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 264. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 265. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 266. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 267. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 268. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 269. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 270. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 271. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 272. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 273. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 274. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 275. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 276. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 277. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 278. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 279. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 280. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 281. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 282. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 283. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 284. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 285. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 286. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 287. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 288. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 289. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 290. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 291. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 292. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 293. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 294. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 295. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 296. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 297. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 298. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 299. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 300. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 301. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 302. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 303. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 304. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 305. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 306. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL & RENAL REPLACEMENT, 2017-2032 (USD MILLION)
TABLE 307. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGIC MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 308. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONSERVATIVE & SUPPORTIVE MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 309. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PROCEDURAL INTERVENTIONS, 2017-2032 (USD MILLION)
TABLE 310. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2017-2032 (USD MILLION)
TABLE 311. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 312. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 313. SOUTH KOREA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 314. SOUTH KOREA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 315. SOUTH KOREA ACUTE

Companies Mentioned

  • Fresenius Medical Care AG
  • Baxter International, Inc.
  • B. Braun SE
  • DaVita Inc. by Optum, Inc.
  • Medtronic plc
  • Asahi Kasei Medical Co., Ltd.
  • Nikkiso Co., Ltd.
  • Nipro Corporation
  • bioMérieux SA
  • AstraZeneca PLC
  • Outset Medical, Inc.
  • Evotec SE
  • Siemens Healthineers AG
  • Abbott Laboratories
  • Terumo Corporation
  • Sysmex Corporation
  • Takeda Pharmaceutical Company Limited
  • SBI Biotech Co., Ltd.
  • Rockwell Medical, Inc.
  • Astellas Pharma Inc.
  • Medica S.p.A.
  • Alloksys Life Sciences
  • CalciMedica Inc.
  • CardioRenal Systems, Inc.
  • CSL Limited
  • Eliaz Therapeutics Inc.
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies Inc.
  • Novartis AG
  • Silver Creek Pharmaceuticals, Inc.
  • TORAY MEDICAL CO,.LTD.

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.96 Billion
Forecasted Market Value ( USD ) by 2032 $ 4.73 Billion
Compound Annual Growth Rate8.0%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Acute Kidney Injury Treatment Market - Global Strategic Business Report - Product Image

Acute Kidney Injury Treatment Market - Global Strategic Business Report

  • Report
  • 366 Pages
  • Global
From
Acute Kidney Injury - Pipeline Insight, 2026 - Product Image

Acute Kidney Injury - Pipeline Insight, 2026

  • Clinical Trials
  • 80 Pages
  • Global
From
Continuous Renal Replacement Therapy Market - Global Forecast 2026-2032 - Product Image

Continuous Renal Replacement Therapy Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Acute Kidney Injury Drug Pipeline Analysis Report 2026 - Product Image

Acute Kidney Injury Drug Pipeline Analysis Report 2026

  • Drug Pipelines
  • 150 Pages
  • Global
From
Acute Renal Failure (ARF) Market Report 2026 - Product Image

Acute Renal Failure (ARF) Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Renal Failure Drug Market

The Renal Failure Drug market is a subset of the larger Liver and Kidney Disorders Drugs market. It is composed of drugs used to treat renal failure, a condition in which the kidneys are unable to filter waste from the blood. These drugs are used to reduce the amount of waste in the blood, as well as to reduce the risk of complications associated with renal failure. Common drugs used to treat renal failure include diuretics, ACE inhibitors, and angiotensin receptor blockers. Additionally, drugs such as erythropoietin and iron supplements are used to treat anemia, a common complication of renal failure. Some companies in the Renal Failure Drug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.